In particular, liquid biopsy is routinely used to detect clinically actionable variants within exons 18-19-21-21 EGFR sensitive mutations when tissue material is inadequate, thus helping to stratify NSCLC patients for first- or second-generation tyrosine kinase inhibitors (TKIs). This evidence concerns the gene EGFR and non-small cell lung carcinoma.